Obinutuzumab in Primary FSGS

NCT04983888 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Primary Focal Segmental Glomerulosclerosis

Interventions

DRUG: Obinutuzumab

Sponsor

Mayo Clinic

Collaborators

[object Object]